North American capsule endoscopy market seeks minimally invasive procedures
Within the North American region, Canada is anticipated to see the strongest growth at 7% CAGR, followed by Mexico with 6.2% and the US with 6.1%.
The US makes up the largest portion of the North American capsule endoscopy market. Market growth in North America is largely driven by the increasing population, the rising incidence of gastrointestinal diseases and a growing preference among patients and providers for minimally invasive procedures. Technological advancements aimed at enhancing imaging quality and the control capabilities of these capsule devices are further accelerating market adoption.
Capsule endoscopy involves the utilisation of small medical devices, typically weighing between 1.9 grams and 4 grams. These capsules are equipped with a battery, light source, camera and transmitter. Once ingested by the patient, the capsule travels through the digestive tract, transmitting detailed images from the oesophagus, stomach and small bowel to an external receiver.
The market is growing as new applications for capsule endoscopy emerge, replacing traditional endoscopic procedures. Medtronic holds a dominant position in North America, with 89.4% of market share. Continued innovation and expanded indications for capsule endoscopy are expected to sustain robust market growth throughout the forecast period.
"North American capsule endoscopy market seeks minimally invasive procedures" was originally created and published by Medical Device Network, a GlobalData owned brand.
The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
Earnings To Watch: Pediatrix Medical Group (MD) Reports Q2 Results Tomorrow
Pediatric healthcare provider Pediatrix Medical Group (NYSE:MD) will be reporting earnings this Tuesday before market open. Here's what investors should know. Pediatrix Medical Group beat analysts' revenue expectations by 1.6% last quarter, reporting revenues of $458.4 million, down 7.4% year on year. It was a very strong quarter for the company, with an impressive beat of analysts' same-store sales estimates and a solid beat of analysts' EPS estimates. Is Pediatrix Medical Group a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting Pediatrix Medical Group's revenue to decline 7.9% year on year to $464.4 million, a deceleration from its flat revenue in the same quarter last year. Adjusted earnings are expected to come in at $0.42 per share. The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. Pediatrix Medical Group has missed Wall Street's revenue estimates four times over the last two years. Looking at Pediatrix Medical Group's peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. The Ensign Group delivered year-on-year revenue growth of 18.5%, beating analysts' expectations by 0.7%, and CVS Health reported revenues up 8.4%, topping estimates by 5.1%. The Ensign Group traded up 8.7% following the results while CVS Health's stock price was unchanged. Read our full analysis of The Ensign Group's results here and CVS Health's results here. Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Pediatrix Medical Group is down 10.9% during the same time and is heading into earnings with an average analyst price target of $17.14 (compared to the current share price of $11.98). Today's young investors likely haven't read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
Medscape
2 hours ago
- Medscape
FDA Calls for Better Opioid Safety Labeling
The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication. The changes are based on observations from a May meeting between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, which met to discuss two postmarketing requirement studies that assessed risk for abuse, addiction, and overdose in long-term use of opioid analgesics. One of the observational studies showed that over 12 months of use, 1%-6% of the more than 2000 total participants met criteria for opioid addiction, 9% met criteria for prescription opioid abuse, and 22% met criteria for prescription opioid misuse. In the second study, 5-year cumulative incidence estimates for opioid overdose-related death ranged from 1.5%-4.0%. In addition, 17% of first opioid overdoses over the entire 5-11 year study period were fatal. The new safety-labeling requirements are a result of these findings, committee and public comments from the meeting, and recognition that there is currently an 'absence of adequate and well-controlled studies on long-term opioid effectiveness,' the FDA noted in a press release. 'The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,' FDA commissioner Marty Makary, MD, said in the release. 30-Day Warning The FDA has also called for a new prospective, randomized controlled trial to be conducted that will focus primarily on assessing risks and benefits of opioids used over the long term. For now, the updated labeling should include a better explanation of risks, stronger warnings about higher doses, clarification about use limits, an emphasis that long-acting or extended-release opioids should only be used if shorter-acting opioids or other medications have proven inadequate, and a reminder about serious harm that can come if a patient who becomes physically dependent does not stop opioid use. Additionally, the revised labels should provide information on possible opioid-related problems with the esophagus; on opioid overdose reversal agents; on toxic leukoencephalopathy, which can occur after overdose; and on negative drug-drug interactions, including gabapentinoids. 'This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring,' Makary said. The release noted that OxyContin's drug application was first approved without supportive long-term use data. The FDA added that manufacturers have 30 days to submit the newly required labeling updates for review.
Yahoo
2 hours ago
- Yahoo
QuidelOrtho (QDEL) Q2 Earnings Report Preview: What To Look For
Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) will be reporting results this Tuesday afternoon. Here's what you need to know. QuidelOrtho met analysts' revenue expectations last quarter, reporting revenues of $692.8 million, down 2.6% year on year. It was a mixed quarter for the company, with a solid beat of analysts' EPS estimates but a slight miss of analysts' full-year EPS guidance estimates. Is QuidelOrtho a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting QuidelOrtho's revenue to decline 4.1% year on year to $611 million, in line with the 4.2% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.01 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. QuidelOrtho has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 4.2% on average. Looking at QuidelOrtho's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 3.5%, beating analysts' expectations by 1%, and Hologic reported revenues up 1.2%, topping estimates by 1.7%. GE HealthCare traded down 8.3% following the results while Hologic was up 2.9%. Read our full analysis of GE HealthCare's results here and Hologic's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. QuidelOrtho is down 21.9% during the same time and is heading into earnings with an average analyst price target of $47.14 (compared to the current share price of $22.81). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
